Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $45.53

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has received an average recommendation of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $45.59.

APLS has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Scotiabank raised their price objective on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research report on Wednesday. HC Wainwright restated a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Royal Bank of Canada decreased their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group dropped their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd.

Insider Activity at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. This trade represents a 3.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the completion of the sale, the chief financial officer now directly owns 88,100 shares of the company's stock, valued at approximately $2,528,470. The trade was a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,054 shares of company stock worth $1,952,719. 6.80% of the stock is owned by company insiders.

Remove Ads

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors have recently modified their holdings of APLS. EverSource Wealth Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares during the last quarter. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Signaturefd LLC raised its holdings in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after acquiring an additional 918 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at approximately $83,000. Finally, US Bancorp DE boosted its stake in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after acquiring an additional 1,327 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Apellis Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ APLS traded down $0.48 during mid-day trading on Monday, reaching $22.52. 2,652,275 shares of the company were exchanged, compared to its average volume of 2,080,725. Apellis Pharmaceuticals has a 1 year low of $21.70 and a 1 year high of $58.12. The firm has a 50-day moving average of $26.42 and a 200 day moving average of $29.16. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -11.09 and a beta of 0.85. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. During the same period in the prior year, the firm posted ($0.73) earnings per share. The company's quarterly revenue was up 45.2% on a year-over-year basis. On average, research analysts expect that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).